A federal district court judge in Newark delayed the planned criminal sentencing of Purdue Pharma by one week after members of the public and victims showed up at a hearing initially set to be held remotely. The postponement to April 28 was announced during proceedings on April 21 as U.S. District Judge Madeline Cox Arleo said she wanted to ensure that victims and the public had an opportunity to be heard in person before concluding the case.
At the scheduled hearing the court had been expected to accept Purdue’s 2020 guilty plea, which would trigger criminal penalties totaling $5.5 billion - a $3.5 billion criminal fine plus $2 billion in criminal forfeiture - tied to the company’s role in marketing opioid painkillers. Those penalties are integrated with a broader bankruptcy settlement under which Purdue would dissolve and channel assets toward a $7.4 billion fund to compensate those harmed by the opioid crisis.
The change in the hearing format followed the physical presence of protesters and members of the public in the courtroom, as well as at least one remote participant who interrupted the proceedings by shouting, "This is not justice!" while the judge was speaking. In response to those developments Judge Arleo emphasized the centrality of victims to the plea process, stating: "In this plea, the single most important people that should be heard are the victims." She added, "If the public and victims wish to be heard in person, I’m going to accommodate that."
Federal prosecutors and defense counsel had previously arranged for victim impact statements to be submitted and for eight victims to speak at the hearing, describing their experiences of addiction, loss and suffering. Several written statements already filed in court urged the judge to reject the plea arrangement on the grounds that the agreement allowed company owners and executives to avoid individual prosecution.
Purdue reached its criminal plea agreement in 2020, admitting to charges that included aggressively marketing prescription opioids to doctors who diverted the drugs for illegal use, defrauding the federal government by evading safeguards designed to curb illegal opioid distribution, and paying kickbacks to prescribers to increase opioid sales. The company had previously entered a guilty plea in 2007, admitting it misled health care professionals and federal regulators about OxyContin’s addiction and misuse risks.
The sentencing is an important condition for completing Purdue’s bankruptcy plan, which would dissolve the company and direct its remaining assets toward compensating opioid creditors - primarily state and local governments that the settlement says should use funds for abatement efforts such as addiction treatment. Under a Justice Department agreement struck after Purdue filed for bankruptcy in 2019, most of the criminal fines will remain unpaid in exchange for allowing the company to allocate its assets to repay other opioid creditors. The federal government agreed to forgo repayment for all but $225 million of the fines and penalties so those funds could be redirected toward broader opioid remedies.
The settlement structure includes significant contributions from the company’s owners. Members of the Sackler family have committed at least $6.5 billion to support the bankruptcy settlement. Purdue is one among a range of drug makers, distributors and pharmacy operators that have collectively agreed to pay roughly $57 billion to resolve claims brought by states and local governments alleging their roles in fueling the opioid epidemic, which the article notes has claimed more than 1 million lives in the United States since 2000.
Requests for comment from Purdue were not immediately answered, and the U.S. Department of Justice declined to comment on the scheduling change. With the sentencing now moved, the court will hear victim statements in person on the new date before deciding whether to accept the plea agreement and the associated criminal penalty terms.
Context and procedural significance
The postponed hearing is procedural but consequential: it represents one of the final judicial steps required to implement a complex bankruptcy-mediated settlement that reallocates corporate assets to public and private claimants. The presence of victims and members of the public at the hearing prompted the court to prioritize in-person participation, underlining the procedural weight courts place on victim input in high-profile pleas tied to mass-harm litigation.